
Opinion|Videos|January 31, 2025
Patient Selection for Aflibercept 8 mg
Panelists discuss how ideal candidates for aflibercept 8 mg include patients with stable disease on current anti-VEGF therapy who seek reduced treatment burden, newly diagnosed patients, and those demonstrating good response to initial loading doses.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- Who is the ideal patient for aflibercept 8 mg?
Newsletter
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times Europe
1
FLORetina 2025: New horizons in research and risk management for ROP
2
FLORetina 2025: Remotely managing patients with neovascular age-related macular degeneration
3
FLORetina 2025: Enrico Borrelli on reframing retinal disease through the lens of choroidal health
4
FLORetina 2025: Antithrombotic use examined in wet AMD submacular hemorrhage
5














































